Management
Christian Schaub, Co-founder, CEO and President
- Serial entrepreneur, business and start-up coach, keynote speaker
- M.Sc. in engineering, ETH Zurich
- Manages Redbiotec’s operations and growth to scientific leadership in bacterial and protein engineering
- Raised > CHF 20 mn capital for the company
- Headed the Pfizer deal (Redbiotec Spin-off Redvax sold to Pfizer)
- Led Redbiotec in closing deals with other pharma companies including Roche, Merck and Sanofi Pasteur
Dr. Corinne John, Co-founder, Executive Vice President
- Ph.D. in biochemistry, ETH Zurich
- Research at Harvard Medical School, USA
- Technology entrepreneurship degree from the executive school of the HSG
- W.A. de Vigier Prize Winner 2007
- Responsible for Human Resources and IP Strategy at Redbiotec
- Member of core M&A team leading the Pfizer deal
Dr. Lilli Stergiou, CSO
- Ph.D. in Molecular Biology and Genetics, Uni Zurich
- > 18 years of cross-disciplinary biomedical research experiences
- Joined Redbiotec in 2012. Appointed CSO in 2017
- Head of Herpes Immunotherapy Program
- Responsible for overseeing all research programs at Redbiotec
- Member of the core M&A team leading the Pfizer deal
- Founding member of the non-profit organization LSZYSN
Dr. Marina Studart, Senior Scientist, Project Leader – Gene Therapy
- Ph.D. in Biochemistry, ETH Zurich
- > 13 years of cross-disciplinary biomedical research experiences
- Joined Redbiotec in 2013
- Formerly responsible for the development of protein engineering platform prior to the Pfizer deal, and Co-Leader of the Oncology Program
- Currently Project Leader of Gene Therapy
Board of Directors
Christian Schaub, Chairman of the board, CEO and co-founder
Dr. Michael Sidler, Member of the board, Partner/co-founder at Redalpine Venture Partners AG
Dr. Michael Sidler joined the Redbiotec Board in 2009. Michael is a founding member of Redalpine Venture Partners AG, Zurich and is General Partner for the Redalpine Capital I fund (Luxemburg). Before becoming an Investor, he was responsible for Corporate Investments and M&A at Prionics, a Biotech Startup based in Schlieren. From 1998 to 2003, Michael worked for The Boston Consulting Group in Zurich and Toronto in different functions as a project manager. Michael is in various organizations, juries, and advisory boards for the development and support of start-up companies such as CTI Startup, Venturekick, CTI Invest, SECA, Technopark Zürich und Glatec. In addition to his engagement in Zurich, he is a partner at Intro International AS, a Norwegian company commercializing emerging technologies. He studied biology at the University of Zurich and received his PhD in 1998.
Dr. Corinne John, Member of the board, co-founder
Dr. med. Hans-Peter Richard, Member of the board, Investor
Dr. Hans-Peter Richard is a Medical Doctor based in Switzerland and a visiting lecturer at the Univ. of Bern. As an active private investor, he partners with a venture capital fund and manages direct investments in start-ups and fast-growing companies, with a strong focus on life sciences. A former board member of the Oettinger Davidoff Group, Dr. Richard is also a board member at several other companies.
Dr. Winfried Mayer, Member of the board, Investor
Dr. Winfried Mayer was the former Head of Manufacturing at Roche Pharmaceuticals, and advisor to Chugai Pharmaceutical, Japan.